GlassScriptPhysician profile
Scott Rappe
NPI 1922249267
$2,782.00
in general payments reported to CMS, 2019-2025
27 companies · $753 in 2025
The $753 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $120 · 2021: $234 · 2022: $233 · 2023: $512 · 2024: $742 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,049.57 | 2021-2025 | |
| Novo Nordisk INC | $242.69 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $230.92 | 2019-2024 | Zepbound, Jardiance, Trulicity |
| Pfizer INC. | $218.03 | 2023-2025 | |
| Amgen INC. | $149.46 | 2022-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.56 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $86.96 | 2022-2025 | Airsupra, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $86.50 | 2022 | |
| Allergan, INC. | $61.94 | 2019-2020 | |
| Axsome Therapeutics, INC. | $56.58 | 2024-2025 | Symbravo, Auvelity |
| Sunovion Pharmaceuticals INC. | $54.62 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $52.21 | 2021 | |
| Mannkind Corporation | $49.88 | 2025 | |
| Mylan Specialty L.P. | $45.46 | 2019-2024 | Yupelri |
| Glaxosmithkline, LLC. | $39.89 | 2024-2025 | Trelegy Ellipta, Arexvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $32.68 | 2025 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.38 | 2024-2025 | Xifaxan |
| Dexcom, INC. | $23.79 | 2024 | Dexcom G6 Transmitter |
| Tempus Ai, INC | $21.54 | 2024 | |
| Exact Sciences Corporation | $19.16 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $18.90 | 2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $18.67 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.64 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $18.59 | 2024 | Nexletol |
| Sumitomo Pharma America, INC. | $15.22 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $15.04 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rappe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.